Die Aktie des Jahres - 500 Beiträge pro Seite

[BörsenkennerCgn]

02.01. 18:41
BSE: Orchid BioSciences explodieren

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Die Titel des kleinen Biotech-Unternehmens Orchid BioSciences schiessen heute erneut um bislang 21,62 Prozent nach oben auf 2,25 Dollar. Im Mai 2003 war die Aktie noch für 33 Cents zu haben.

Die Börsianer hoffen weiterhin, dass der Schnelltest des Unternehmens für die Traberkrankheit bei Schafen auch für BSE-Tests einsatzfähig sein könnte. Orchid gelten in diesem Bereich als führender Anbieter, deren Verfahren nicht nur eine Diagnose liefern kann, sondern gleichzeitig Aussagen darüber machen soll, inwieweit die Tiere tatsächlich resistent gegen die Krankheit sind. Die Traberkrankeit bei Schafen und der Creutzfeld-Jakobs-Erreger sind biologisch verwandt.


Eine Steigerung mit höchstem Volumen heißt sicher,
dass einige wieder mehr wissen.

[heikekarina]

sag bloss, Du bist erst heute eingstiegen?
Traurig, Traug, Traurig

[BörsenkennerCgn]

Hallo,

sicher nicht.Ich bin seit 0,90 Euro drin.
Wollte schon genervt aussteigen, aber jetzt ist die Freude
sicher groß. Nur was wird nächste Woche???ß

[BörsenkennerCgn]

Ich glaube nicht, das diese Nachricht

der alleinige Grund für diesen Anstieg ist.

Oder welche Meinung habt Ihr???


Das Unternehmen, das Marktführer bei Testsystemen für die Scrapie-Krankheit (Schaf-Krankheit ähnlich des Rinderwahnsinns) ist, wird in Großbritannien einen Großteil des von der Regierung zur Verfügung gestellten Budgets zur Bekämpfung der Schaf-Krankheit in Form von Test-Aufträgen bekommen. Das Volumen beträgt den Angaben zufolge mehrere zehn Mio. Dollar.

[BörsenkennerCgn]

Tom Cruise ist bei Dreharbeiten in Neuseeland angeblich nur knapp dem Tod entronnen.



Bei einem Schwertkampf für den Film "Last Samurai" wäre er wegen eines defekten mechanischen Pferdes fast enthauptet worden, sagte der 41-Jährige der Zeitschrift "TV Movie".




Dass er den Zwischenfall lebend überstand, habe er dem japanischen Schwertkämpfer Hiroyuki Sanada zu verdanken.

"Er konnte sein Schwert gut zwei Zentimeter vor meinem Nacken stoppen", sagt Cruise.
In dem 100-Millionen Dollar-Film spielt Cruise einen todesmutigen Kämpfer, der nach seiner Wandlung zum Samurai im Jahr 1876 mit Schwert und Pferd gegen Japans Armee in den Krieg zieht.

[MoneymakerIII]

Tja, hätte man das mechanische Pferd mit dem Trabertest von Orchid getestet, wäre aufgefallen, dass es nicht ganz dicht ist und die Versicherung von Cruise hätte nicht kurz vorm Herzkasper gestanden....

mfg
Money

[BörsenkennerCgn]

Super Kommentar.

Möchtest Du nicht Harald Schmidt mit dt beerben??

[MoneymakerIII]

Gerne spiele ich hier den Schmidt und poste lockere Zoten, asiatische Weisheiten und ergehe mich in reichsdeutschen Plattitüden - für Unterhaltung muss ja auch gesorgt werden. Nur wer bezahlt mir von euch 20.000 Euro pro Tag dafür?
Hab eben eine Flaschenpost bekommen, die Infos von Mess Mining Inc. (siehe Thread: +++ HOT +++ UNGLAUBLICH +++) enthielt, beigefügt war auch eine Entschuldigung bezüglich der Nicht-Herausgabe von Informationen am 20. Dezember 2003 wie vorher groß angekündigt (Thread: *** NEWS im Anflug ***).

mfg
Money

[Lettin29]

Schluß auf Tageshoch und ne schöne weiße Kerze.

Ich denk mal, Montag gehts noch ein wenig weiter.

[Sugar2000]

mein Einstieg lag damals bei 10€! Also ich habe Zeit

[suncomesout]

@sugar

Vielleicht wirds ja doch bald was...
TEPNEL COMPLETES ACQUISTION OF ORCHID`S DIAGNOSTICS UNIT




PRINCETON, N.J., and MANCHESTER, U.K., Jan. 22, 2004 - Orchid BioSciences, Inc. (Nasdaq: ORCH) and Tepnel Life Sciences PLC (AIM: TED) today announced that Tepnel has completed its acquisition of certain assets and liabilities of Orchid’s diagnostics unit. The diagnostics unit, which will now operate as Tepnel Lifecodes Corporation in the U.S. and Tepnel Diagnostics Ltd. in Europe, provides systems, consumables and services for HLA testing for organ transplantation, and genetic screening for disease predisposition, as well as certain related support services.

Under the terms of the agreement, Tepnel has acquired the product and services business of Orchid Diagnostics unit in the U.S., the U.K. and Belgium, including its LifeMatch™ system and consumable product line for HLA testing and its Elucigene™ product line for testing of certain genetic diseases, as well as certain liabilities of the diagnostics business, for $3.45 million in cash, subject to a further adjustment in respect of net assets once completion accounts have been prepared and agreed by both parties. Orchid and Tepnel agreed among other things, to a revised purchase price of $3.45 million to reflect changing market conditions. Tepnel has taken control of the facilities formerly occupied by Orchid’s diagnostic unit in Stamford, Connecticut and Brussels, Belgium, and has indicated its intention to retain all of the diagnostics unit’s employees.

About Tepnel Life Sciences PLC
Tepnel is a UK-based international life sciences instrumentation and services company with a ‘tri-polar’ strategy focused on providing the biomedical industry with high-throughput automated DNA purification systems, manual DNA purification kits and reagents, as well as scientific services for nucleic acid purification, drug analysis, genotyping and genetically modified foods. Tepnel was founded in 1992 to exploit DNA technology generated at UMIST (University of Manchester Institute of Science and Technology) and is quoted on the AIM market of the London Stock Exchange (AIM: TED).


SCO

[suncomesout]

Aktuelle Entwicklung:

Orchid BioSciences Announces Conversion of Preferred Stock and Provides Financial Guidance Update


PRINCETON, N.J., Feb. 10 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that all of its outstanding convertible preferred stock has been converted into common stock. As a result, Orchid had approximately 94.7 million common shares outstanding as of February 9, 2004. Additionally, Orchid provided an update to its financial guidance for 2003 and 2004.

"In view of the many near-term growth opportunities facing Orchid, I believe the next step in our restructuring is to further strengthen our capital structure in order to better position the company for profitable growth," said Paul J. Kelly, M.D., chief executive officer of Orchid. "With completion of this initial phase of our capital restructuring effort, we look forward to the next phases, which we expect will include our proposed reverse stock split and, at an appropriate time, raising additional capital to help fund Orchid`s next phase of growth."

Orchid re-affirmed and expanded its financial guidance for the full year 2003 and for 2004:

2003 Financial Guidance Update
-- Orchid continues to expect top-line revenues of approximately $50
million for the full year 2003.
-- Orchid estimates that its 2003 year-end free cash balance will be
approximately $10 million, which includes $1 million of the $3.45
million purchase price paid to Orchid in connection with the sale of
its Diagnostics unit. This estimate differs from the company`s
previous guidance of $11 million to $13 million because the
transaction closed in January 2004 and as a result the full purchase
price could not be recorded in 2003.
-- Orchid expects its average gross margin to be in the low-to-mid 40
percent range for the full year 2003.

2004 Financial Guidance Update
-- Orchid expects an increase in its 2004 top-line revenues of
approximately 20 percent over its expected 2003 top-line revenues.
-- Orchid expects its 2004 average gross margin to improve by
approximately 2 to 4 percentage points over its expected 2003 gross
margins.
-- Orchid expects its full year 2004 total operating expenses to decrease
by approximately 10 percent compared to its expected total operating
expenses for 2003.
-- Orchid continues to expect to achieve positive cash flows from
operations in the first half of 2004.
-- Orchid expects to achieve positive operating income for the full year
2004.

Fourth Quarter and Full Year 2003 Financial Results

Orchid`s fourth quarter and full year 2003 financial results are scheduled to be released on Thursday, February 26, 2004, and an investor conference call with management will be held that morning to discuss the financial results and recent operating highlights as well as 2004 guidance. The company will announce the call details on or about February 19, 2004.

Reverse Stock Split

As previously announced, Orchid is seeking shareholder approval to implement a reverse stock split ranging from 1-for-3 shares to 1-for-7 shares. A Special Meeting of Shareholders will be held on February 27, 2004 to consider this proposal.

SCO

[suncomesout]

Wow!
Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 100
2. TOURNIGAN GOLD COR 69
3. NEWTECH RESOURCES LT... 39
4. DEUTSCHE ENTERTAINME... 34
5. QSC AG 32
6. UNIVERSAL EXPRESS IN... 22
7. MLP AG 21
8. IM INTERNATIONALMEDI... 21
9. ORCHID BIOSCIENCES, ... 20
10. OBDUCAT AB 19
11. WCM BETEILIGUNGS-UND... 16
12. FREENET.DE AG 16
13. Realtos Grund- und B... 16
14. AMBRI LTD 16
15. MORPHOSYS AG 14



SCO

[suncomesout]

Und nun schon auf Platz 4..
1. PROVIDENTIAL HLDGS ... 106
2. TOURNIGAN GOLD COR 70
3. NEWTECH RESOURCES LT... 40
4. ORCHID BIOSCIENCES, ... 36

SCO

[Paepstin]

Für unseren Freund Ozonloch,
Päpstin proudly presents:

Topstocks der letzten 24 Stunden

1. PROVIDENTIAL HLDGS ... 109
2. TOURNIGAN GOLD COR 70
3. ORCHID BIOSCIENCES, ... 48
4. NEWTECH RESOURCES LT... 41

[suncomesout]

Damit alle wissen, worums heute geht:

Orchid BioSciences to Host Conference Call to Announce Fourth Quarter and Full Year 2003 Financial Results


PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH) will release its fourth quarter and full year 2003 financial results before the U.S. financial markets open on Thursday, February 26, 2004 and is hosting a conference call that also will be broadcast live over the Internet that day at 10:00 a.m. ET. Participating members of Orchid senior management include Paul J. Kelly, M.D., chief executive officer and Michael E. Spicer, chief financial officer. Management will discuss financial results for the fourth quarter and full year 2003 as well as Orchid`s recent operating highlights. A question-and-answer session will follow management`s discussion.
What: Orchid BioSciences, Inc. Fourth Quarter and Full Year 2003 Financial Results Conference Call
When: Thursday, February 26, 2004, 10:00 a.m. ET
How: The dial-in number is 1-973-317-1168
A live Webcast of the conference call and a replay will also be available via the Investor Relations section of the company`s website at www.orchid.com. All interested parties are encouraged to listen to the live conference call or the live or archived Webcast.


Suncomesout

[suncomesout]

Na bitte: Zahlen besser als erwartet und gute Aussichten für 2004!

Orchid BioSciences Reports Fourth Quarter And Full Year 2003 Financial Results
Thursday February 26, 7:03 am ET
-- Achieves top-line revenue target of $50 million for 2003 and record quarterly revenue of $13.7 million
-- Achieves significant reductions in operating expenses and operating losses in 2003 compared to 2002
- Operating expenses decreased by 61% in fourth quarter and 47% for full year
- Operating loss from continuing operations narrowed to $2.0 million in fourth quarter and decreased by 80% for full year

Alles Einsteigen!

Suncomesout

[Paepstin]

[suncomesout]

Orchid Awarded Immigration Identity Testing Contract by New Zealand Government


Further Expands Orchid`s International Immigration Testing Services

PRINCETON, N.J. and ABINGDON, England, April 13 /PRNewswire-FirstCall/ -- Orchid BioSciences, Inc. (Nasdaq: ORCHD) today announced that its Orchid Europe operation has been awarded an exclusive DNA analysis contract by the New Zealand Immigration Service. Orchid will provide DNA testing services to individuals seeking to migrate to New Zealand, when they cannot establish their identities and biological relationships by conventional means. This three-year contract was awarded to Orchid following a competitive bid process and is potentially renewable for an additional two years. Further details were not disclosed.

" It is critical that an approved and reliable system of DNA analysis be available to assist residence applicants where documentation to establish the necessary relationships between themselves and their sponsors does not exist or is unreliable," said Gill Johnson of the New Zealand Immigration Service. " We believe Orchid can deliver what we require and we are looking forward to working with them."

Orchid, which markets several of its services under the Cellmark brand, will provide DNA testing services under the contract to determine the biological relationships between applicants and their family members, including sponsors in New Zealand . Like most countries, New Zealand allows immigration of certain relatives of its citizens and permanent residents. DNA testing is particularly important for applicants from countries that do not have records systems that enable applicants to otherwise satisfy the New Zealand Immigration Service of the necessary family relationships.

" DNA relationship analysis is increasingly being used as part of government immigration programs and often requires the complex analysis that we specialize in," said David Hartshorne, commercial director of Orchid Europe. " Orchid has an established reputation for quality and accurate testing and is at the forefront of developing new technologies and services to assess claimed relationships. We are delighted to be the provider of choice for the New Zealand Immigration Service."

In addition to this contract with the New Zealand Immigration Service, Orchid is also the exclusive provider of immigration DNA testing for the UK government`s UKVisa`s program, and the sole supplier to the Norwegian government`s immigration department. Work under this contract will be provided at Orchid`s Abingdon facility in the U.K.